Trial reportArchives of virology2021
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
Trial report in Archives of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to trial NCT04351295 (Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment), which is not on this map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.BMC infectious diseases · 2022Pooled it
- Effectiveness of favipiravir in COVID-19: a live systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Pooled it
- Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2021Pooled it
- Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.Frontiers in public health · 2021Pooled it
- The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.European journal of pharmacology · 2022Trial
- Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting.International journal of general medicine · 2022Trial
- RETRACTED: Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial.The American journal of tropical medicine and hygiene · 2021Trial
- Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.International immunopharmacology · 2021Trial
- When randomisation goes horribly wrong: examples of major failures of randomisation and strategies to avoid them.Trials · 2025Review
- Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients.Scientific reports · 2025Article
- Insights into the sustainability of liquid chromatographic methods for favipiravir bioanalysis: a comparative study.RSC advances · 2024Review
- Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19.Inflammopharmacology · 2024Article
- Recent Trends in Nanomaterial Based Electrochemical Sensors for Drug Detection: Considering Green Assessment.Current topics in medicinal chemistry · 2024Review
- Synergistic effect of gold nanoparticles anchored on conductive carbon black as an efficient electrochemical sensor for sensitive detection of anti-COVID-19 drug Favipiravir in absence and presence of co-administered drug Paracetamol.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2023Article
- The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2023Observational
- Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand.The Lancet regional health. Southeast Asia · 2023Article
- Evaluation of the effect of favipiravir on patients with COVID-19.Journal of family medicine and primary care · 2023Article
- Retraction of Clinical Trials about the SARS-CoV-2 Infection: An Unaddressed Problem and Its Possible Impact on Coronavirus Disease (COVID)-19 Treatment.International journal of environmental research and public health · 2023Article
- Synthesis of conjugates of (aRussian chemical bulletin = Izvestiia Akademii nauk. Seriia khimicheskaia · 2023Article
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Expression of concern · 2021-08-03Concerns/Issues about Data · Updated to Retraction ·
- Retraction · 2021-11-22Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Error in Methods · Upgrade/Update of Prior Notice(s) ·
- Retracted
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.